The aim of the production is to generate DCs that can efficiently cross-present the DC-loaded (pulsed) tumor antigens and induce an in vivo Th1 response with the subsequent expansion of cytotoxic tumor antigen-specific CD8+ T cells [27,28]. Here, CD8A is linked to neoplasm.